A First-in-human, Phase I, Open-label Study of the ATM Inhibitor M4076 in Participants With Advanced Solid Tumors (DDRiver Solid Tumors 410)
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Lartesertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms DDRiver Solid Tumors 410
- Sponsors EMD Serono Research & Development Institute
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Results (n=22) presented at the 114th Annual Meeting of the American Association for Cancer Research
- 11 Jan 2023 Status changed from recruiting to active, no longer recruiting.